Baron Funds, an investment management company, released its "Baron Health Care Fund" fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging quarter for the larger health care industry. A copy of the letter can be downloaded here. The fund declined 9.58% (Institutional Shares) in the quarter compared to a 9.75% decline for the Russell 3000 Health Care Index (benchmark) and a 2.63% gain for the Russell 3000 Index (the Index). For the full year 2024, the fund appreciated 1.55% compared to 3.48% and 23.81% gains for the indexes. In addition, please check the fund's top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as Edgewise Therapeutics, Inc. (NASDAQ:EWTX). Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company, focuses on developing therapies for the treatment of muscle disorders. The one-month return of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) was -3.72%, and its shares gained 49.31% of their value over the last 52 weeks. On February 18, 2025, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stock closed at $26.13 per share with a market capitalization of $2.474 billion.
Baron Health Care Fund stated the following regarding Edgewise Therapeutics, Inc. (NASDAQ:EWTX) in its Q4 2024 investor letter: